Tirzepatide Lowering
Cardiovascular Disease in Non-Diabetics
Many scientists are studying Glucogon-Like Peptide-1 for many reasons, but mainly for diabetics and people with obesity. Some of the things happening that they didn’t expect, are findings that the GLP-1s are helping with other issues, even in those without diabetes.
A group of studies show that Mounjaro/tirzepatide not only lowers HbA1c in diabetics, but are significantly lowering the risk of cardiovascular events including heart disease, heart attacks, strokes, and more.
One day, these medications might be prescribed specifically for that reason, with weight loss being a side-effect rather than the main reason people are taking it. Maybe insurance will pay for it then!
Wegovy Cutting Heart Attacks and Strokes
Moving from tirzepatide (Mounjaro/Zepbound) to semaglutide (Ozempic/Wegovy), it is also proving to lower the rate of heart attacks and strokes.
The New England Journal of Medicine shared the results of a semaglutide study on November 11, 2023. The risk of death from heart failure, heart attacks, and strokes was cut by 20% in a three year period. TWENTY PERCENT! Blood pressure, diabetes, and inflammation also showed improvement soon after beginning the medication.
This reiterates how wonderful these meds are. Again, it might not be too long before they are prescribed to at-risk cardio patients as well as those with Type 2 Diabetes. Love it!
Tirzepatide Greatly Lowers Risk of Cardiac Vascular Disease in Patients
Without Diabetes
In Diabetes, Obesity and Metabolism, the result of a 72 week trial of tirzepatide showed that treatment with tirzepatide greatly reduced the 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD).
This is amazing, too!
Hints of Slow Down for Medical Devices
Due to GLP-1 Meds
From heart monitors to bariatric surgery equipment, the makers of medical devices are quietly nervous. One that initially wondered if they would be phased out one day was the Continuous Glucose Monitor (CGM), but it seems they might be seeing an uptick as people test themselves to see if they qualify for the GLP-1s. I know I would love a CGM to watch my own blood glucoses even on Mounjaro. I meant to ask the Endo and forgot. Dang.
The mechanical tools used in bariatric surgery are also seeing a slow-down, though the makers seem to think it will be temporary, that people will once again use the gastric surgeries to help them lose weight.
I wrote about my own experiences with the Roux-en-Y Gastric Bypass I had in 2001. My Short History from Fen-Phen to Gastric Bypass speaks about the long-term side effects I (and many others who have had an RNY) still have 20+ years later… deficiencies in the body that have to be medically remedied. It’s the worst.
Nestlé is Making “Companion Products”
for GLP-1 Users
SMART!
Nestlé CEO Mark Schneider said he could see products that help limit muscle loss and rapid regain of weight. (You already know I believe once you start the meds, you’ve agreed to take them forever.) He also said the products could have the minerals and other nutrients necessary for those of us on these medications.
Love it!
Retatrutide Kicks Liver Disease’s Ass!
Retatrutide is yet another GLP-1 (+) that Eli Lilly is working on and promises to really do a number on fatty liver disease. Not only is retatrutide a GLP-1, but also an agonist of the glucose-dependent insulinotropic polypeptide (GIP) and adds glucagon receptors to the mix. This is known as a GGG medication. Mounjaro/Zepbound is a GLP-1/GIP medication, however does not have the glucagon receptors included.
80%-93% of people with fatty liver disease on retatrutide, by the 48th week in the trial had so little fat on their livers, they were no longer considered to have fatty liver disease. This is phenomenal!
Loving These Stories!
I’m working to stay on top of the news and share the most life-changing ones for those of us on this journey together… and those that are considering it.
It’s an fantastic ride!